In January 2002, Mr. Smith joined Cambrex Bioproducts as the Business Unit Director of the emerging cell therapy contract manufacturing business. In 2004, he was promoted to Vice President, Business Development, and in December 2005 to Vice President, Cellular Therapeutics. In this role, he assumed responsibility for contract manufacturing, process development, and clinical/commercial development of Cambrex owned Engineered Skin Substitute (ESS) for catastrophic burns. In 2009, two years following Lonza’s acquisition of Cambrex Bioproducts, Mr. Smith became Head of Therapeutic Cell Solutions; with additional responsibilities for biotherapeutic media, process development, viral vaccines and gene therapies. In 2015, Mr. Smith became Vice President , Global Business Development, focusing on strategic agreements and alliances for the Emerging Technologies Business Unit, which includes cell and viral therapy. He is an active member of numerous government expert panels; company executive committees and advisory boards. Under Mr. Smith leadership the cell therapy contract manufactacturing business as grown from start-up to market leader.
Prior to joining Cambrex, Mr. Smith was Vice President, Corporate Development at Claragen, Inc. and Business Unit Director at Invitrogen. Mr. Smith has spent 14 years at The Upjohn Company in various sales and marketing roles, including leading the launch of the Parkinson’s therapeutic, Mirapex.
Mr. David Smith holds a B.S. in Pharmacy from Duquesne University in Pittsburgh, Pennsylvania and a M.B.A. from Wheeling Jesuit University in Wheeling, West Virginia.